Production of monoclonal antibodies against phosphoprotein 65 from human cytomegalovirus

Hybridoma

Volumn 26, Issue 3, 2007, Pages 173-177

  Xu, Li Jun ^a   Yao, Hang Ping ^a   Fan, Jun ^a   Li, Dan ^b   Wu, Nan Ping ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PHOSPHOPROTEIN; PHOSPHOPROTEIN 65; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, VIRAL; BLOTTING, WESTERN; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYBRIDOMAS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; PHOSPHOPROTEINS; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 5;

EID: 34447296443     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2007.008     Document Type: Article

References (23)

1. Cannon MJ and Davis KF: Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 2005;5:70.
2. Pawlowska M and Halola W: CMV infections. Przegl Epidemiol 2004;58(Suppl 1):17-21.
3. Griffiths PD and Walter S: Cytomegalovirus. Curr Opin Infect Dis 2005;18:241-245.
4. Kovacs JA and Masur H: Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000;342:1416-1429.
5. Yamashita M, Ishii T, Iwama N, and Takahashi H: Incidence and clinical features of cytomegalovirus infection diagnosed by cytomegalovirus pp65 antigenemia assay during high dose corticosteroid therapy for collagen vascular diseases. Clin Exp Rheumatol 2006;24:649-655.
6. Carstens J, Andersen HK, Spencer E, and Madsen M: Cytomegalovirus infection in renal transplant recipients. Transpl Infect Dis 2006;8:203-212.
7. Melnick JL, Adam E, and DeBakey ME: Cytomegalovirus and atherosclerosis. Bioessays 1995;17:899-903.
8. Griffiths P: Cytomegalovirus infection of the central nervous system. Herpes 2004;11(Suppl 2):95A-104A.
9. Grce M, Husnjak K, Matovina M, and Milutin N: Human papillomavirus, cytomegalovirus, and adeno-associated virus infections in pregnant and nonpregnant women with cervical intraepithelial neoplasia. J Clin Microbiol 2004;42:1341-1344.
10. Marshall GS and Stout GG: Cytomegalovirus seroprevalence among women of childbearing age during a 10-year period. Am J Perinatol 2005;22:371-376.
11. Siennicka J: Detection of CMV infected cells by flow cytometry-evaluation of MAbs CCH2 and AAC10 directed against early and late CMV antigens. Pol J Microbiol 2004;53:127-129.
12. Gentile G, Picardi A, Capobianchi A, Spagnoli A, Cudillo L, Dentemaro T, Tendas A, Cupeli L, Ciotti M, Volpi, A, et al: A prospective study comparing quantitative cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infect Dis 2006;6:167.
13. Tanaka N, Kimura H, Hoshino Y, Nishikawa K, Kojima S, Nishiyama Y, and Morishima T: Expression of tegument protein pp65 of human cytomegalovirus (CMV) and its application to the analysis of viral-specific cellular immunity in CMV-infected individuals. Arch Virol 2002;147:2405-2417.
14. Emura I: Utility of anti-cytomegalovirus (CMV) pp65 antibody and cytology in CMV antigenemia and CMV disease diagnosis. Kansenshogaku Zasshi 2006;80:501-506.
15. Samhrook J and Russel DW: Molecular Cloning: A Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY, 2001.
16. Johnson SC, Benson CA, Johnson DW, and Weinberg A: Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis 2001;32:815-819.
17. Maine GT, Lazzarotto T, and Landini MP: New developments in the diagnosis of maternal and congenital CMV infection. Expert Rev Mol Diag 2001;1:19-29.
18. Grangeot-Keros L and Cointe D: Diagnosis and prognostic markers of HCMV infection. J Clin Virol 2001;21:213-221.
19. Gyulai Z, Endresz V, Burian K, Pincus S, Toldy J, Cox WI, Meric C, Plotkin S, Gonczol E, and Berencsi K: Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65. IE12 EXOD4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE12 specific CTLs [J]. J Infect Dis 2000;181:1537-1546.
20. Paston SJ, Dodi IA, and Madrigal JA: Progress made towards the development of a CMV peptide vaccine. Hum Immunol 2004;65:544-549.
21. Gallez-Hawkins G, Li X, Franck AE, Thao L, Lacey SF, Diamond DJ, and Zaia JA: DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine 2004;23:819-826.
22. Trivedi D, Williams RY, O'Reilly RJ, and Koehne G: Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 2005;105:2793-2801.
23. Koelle DM and Corey L: Recent progress in herpes simplex virus immunobiology, and vaccine research. Clin Microbiol Rev 2003;96-113.